IQV
NYSEIQVIA Holdings Inc.
Price$158.62+1.45 (+0.92%)
01:30 PM04:00 PM
News · 26 weeks74+267%
2025-11-022026-04-26
Mix5390d
- Insider34(64%)
- Other8(15%)
- SEC Filings6(11%)
- Analyst3(6%)
- Earnings2(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Stamps Sheila A4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Wims Morris Leslie4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaelin William G Jr4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERDirector Leonard John M was granted 1,571 shares, increasing direct ownership by 10% to 16,946 units (SEC Form 4)4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERDirector Goggins Colleen A was granted 1,571 shares, increasing direct ownership by 12% to 14,453 units (SEC Form 4)4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERDirector Danhakl John G was granted 1,571 shares (SEC Form 4)4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Fasano Jim4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERDirector Burt Carol was granted 1,571 shares (SEC Form 4)4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- SECSEC Form S-8 filed by IQVIA Holdings Inc.S-8 - IQVIA HOLDINGS INC. (0001478242) (Filer)
- SECSEC Form 8-K filed by IQVIA Holdings Inc.8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
- PRIQVIA to Announce First-Quarter 2026 Results on May 5, 2026IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http://ir.iqvia.com. To par
- SECAmendment: SEC Form SCHEDULE 13G/A filed by IQVIA Holdings Inc.SCHEDULE 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
- PRIQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life SciencesIQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced at NVIDIA GTC the launch of IQVIA.ai, a unified agentic AI platform purpose-built to help life sciences organizations transform how they operate, make decisions and innovate across clinical, commercial and real-world domains. Combining IQVIA's deep life sciences expertise, Healthcare-grade AI® and data assets with NVIDIA Nemotron, NeMo Agent Toolkit, Dynamo and LangChain, IQVIA.ai is designed to continuously learn from complex operational feedback, while operating securely and in alignment with healthcare regulatory, privacy and quality
- ANALYSTIQVIA upgraded by TD Cowen with a new price targetTD Cowen upgraded IQVIA from Hold to Buy and set a new price target of $213.00
- ANALYSTIQVIA upgraded by Barclays with a new price targetBarclays upgraded IQVIA from Equal Weight to Overweight and set a new price target of $210.00
- ANALYSTRBC Capital Mkts initiated coverage on IQVIA with a new price targetRBC Capital Mkts initiated coverage of IQVIA with a rating of Outperform and set a new price target of $221.00
- PRIQVIA CFO to Speak at Barclays 28th Annual Global Healthcare ConferenceIQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Mike Fedock, executive vice president and chief financial officer, will speak at the Barclays 28th Annual Global Healthcare Conference on Thursday, March 12, 2026, at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and he
- PRIQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare ConferenceIQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 9:20 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intellige
- SECSEC Form DEFA14A filed by IQVIA Holdings Inc.DEFA14A - IQVIA HOLDINGS INC. (0001478242) (Filer)
- SECSEC Form DEF 14A filed by IQVIA Holdings Inc.DEF 14A - IQVIA HOLDINGS INC. (0001478242) (Filer)
- PRIQVIA Releases its 2025 Sustainability ReportIQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today published its 2025 Sustainability Report. The report highlights IQVIA's progress across its People, Public and Planet pillars, consistent with the company's mission to accelerate innovation for a healthier world. IQVIA's 2025 Sustainability Report can be downloaded at: https://www.iqvia.com/-/media/iqvia/pdfs/about-us/sustainability/iqvia-2025-sustainability-report.pdf. Highlights from the report include: Investments in the company's employees. IQVIA's approximately 93,000 employees worldwide are c
- PRIQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery CapabilitiesIQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. These assets include five sites specializing in a range of in vitro drug discovery services, including established laboratory based New Approach Methodologies (NAMs) and a small molecule AI platform, designed to accelerate discovery programs and support growing demand for non animal research methods. Collectively, these assets are underpinned by more than 20 years of curated scientific and ope
- PRIQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access DayIQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ron Bruehlman, chief financial officer, and Mike Fedock, senior vice president, financial planning & analysis and incoming CFO, will speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, at 11:00 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading glo
- INSIDEROfficer Haas Bernd covered exercise/tax liability with 20 shares, decreasing direct ownership by 0.08% to 24,394 units (SEC Form 4)4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDEROfficer Fedock Michael J. covered exercise/tax liability with 123 shares, decreasing direct ownership by 1% to 9,472 units (SEC Form 4)4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
IQV FAQ
7 questionsWhat does IQVIA Holdings Inc. do?
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision...Where does IQV stock trade?
IQVIA Holdings Inc. (IQV) is listed on NYSE.What sector and industry is IQV in?
IQVIA Holdings Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did IQVIA Holdings Inc. go public?
IQVIA Holdings Inc. (IQV) completed its IPO in 2013.What are analysts saying about IQV?
IQVIA Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-03-09.What companies are similar to IQV?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), DHR (Danaher Corporation), GSK (GSK plc). Compare IQV side-by-side with any of them on Quantisnow.How can I track IQV on Quantisnow?
Quantisnow aggregates IQVIA Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IQV to receive live email and push alerts on every new disclosure.